BPC-157
Also known as Body Protection Compound 157, Pentadecapeptide BPC 157, PL 14736, Bepecin
BPC-157 is a 15 amino acid fragment of a protective protein found in human gastric juice. People use it for tendon, ligament, muscle and gut healing, and it is one of the most widely used research peptides in the recovery space.
Reviewed by the amino101 editorial team. , first published .
Quick start
What people commonly do. Not a prescription.- Typical dose
- 250 to 500 mcg
- How often
- once or twice daily
- Where
- Subcutaneous, belly or thigh, or as close to the injury as is practical; oral capsules for gut complaints
- Timing
- any time of day; oral doses are usually taken away from food for gut use
- Effects timeline
- pain and swelling 3 to 7 days, tendon and muscle function 2 to 4 weeks, gut symptoms 1 to 3 weeks
- Storage
- fridge 2 to 8 C once mixed, use within 4 weeks; powder in the freezer or fridge away from light
- Cycle length
- 4 to 8 weeks
- Break between
- 2 to 4 weeks, or stop once the injury has healed and restart only if needed
Overview
BPC-157 is a synthetic peptide made up of 15 amino acids. Its sequence is taken from a larger protective protein that occurs naturally in the stomach lining, which is where the name Body Protection Compound comes from. It was first characterized by a research group in Zagreb, Croatia in the early 1990s, and that same group is responsible for the large majority of published studies on it. It is stable in gastric acid, which is unusual for a peptide and is why it has been studied both orally and by injection.
The animal evidence is extensive. Dozens of rodent studies report faster healing of cut Achilles tendons, crushed muscles, ligament injuries, bone fractures, skin wounds and various gut injuries including ulcers, fistulas and colitis. There are also rodent studies on nerve repair, protection against drug toxicity and vascular effects. The consistent theme is that the peptide promotes new blood vessel growth and cell migration at the site of damage.
Human evidence is thin. A small number of early phase trials were run for inflammatory bowel disease, and one small trial looked at knee pain with intra-articular injection. Results were described as favorable but were never followed by large controlled trials. Almost everything people cite about BPC-157 in humans comes from anecdote. It is also worth knowing that nearly all the rodent work comes from a single lab, so independent replication is limited.
How it works
BPC-157 is thought to work mainly by upregulating growth factor signaling at injury sites. It increases expression of VEGF and its receptor, which drives angiogenesis, the formation of new capillaries that feed a healing wound. It also activates the FAK-paxillin pathway, which helps fibroblasts and tendon cells migrate into damaged tissue and lay down new collagen. In the gut it appears to interact with the nitric oxide system and protect the mucosal barrier. Some researchers also point to modulation of dopamine and serotonin systems as a reason it affects mood and gut motility in animals. Much of this is inferred from rodent tissue, not human data.
Where the research stands
Tendon, ligament and muscle healingModerate evidence
- Achilles and other tendon repair. Rat studies of surgically cut Achilles tendon show faster healing and stronger tendon-to-bone reattachment; no human trial exists.
- Ligament injury. Rodent medial collateral ligament models show improved healing, again with no human data.
- Muscle crush and tear. Rodent studies report restored muscle function after crush injury with both local and systemic dosing.
- Bone fracture. A small number of rodent and rabbit studies show improved fracture healing, which is thin evidence.
Gut lining protection and repairModerate evidence
- Gastric ulcers and NSAID damage. Extensive rodent work shows protection of the stomach lining against NSAIDs and alcohol; this is the area with the deepest animal literature.
- Inflammatory bowel disease. Small early phase human trials for ulcerative colitis were reported as favorable but were never published as full controlled trials.
- Fistulas and colitis. Rodent models of fistula and chemically induced colitis healed faster; human data does not exist.
Nerve and vascular repairEmerging
- Peripheral nerve injury. Rat sciatic nerve studies show faster functional recovery; purely preclinical.
- Blood vessel and clotting effects. Rodent studies report vessel formation and protection against both thrombosis and bleeding, an effect that is not understood in humans.
Joint painWeak or mixed
- Knee pain. One small human series using intra-articular injection reported reduced pain, without a control group.
- rodentAccelerated healing of surgically cut Achilles tendon in rats, with improved biomechanical strength and tendon-to-bone reattachment.
- rodentReduced gastric ulcer formation and protected the stomach lining against NSAIDs and alcohol in rats.
- in vitroPromoted tendon fibroblast migration and survival in culture via FAK-paxillin signaling.
- rodentImproved healing of muscle crush injury and restored function in rodents when given systemically or locally.
- human pilotSmall human trials for ulcerative colitis and knee pain reported tolerability and some benefit, but were never published as full controlled trials.
Rodent and in vitro mean no human data for that finding. Human pilot means small, often uncontrolled. Human RCT means randomized and controlled. Clinical means an approved drug with regulatory data.
Levels over time
Modeled from the half-life. Illustrative, not measured.A half-life of 30 min against dosing every 24 h means each dose has cleared before the next. Nothing stacks; you start from zero every time, and the tissue effect is what carries over.
The short plasma half-life is why once or twice daily dosing is used, and the growth factor signaling it starts at the injury site continues long after the peptide itself is gone.
BPC-157 dosage and protocols
Most people run it for 4 to 8 weeks and then reassess, or simply use it until an injury has healed. There is no loading or tapering, and no human data on whether continuous use is better or worse than cycling.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute soft tissue injury | 500 mcg | twice daily | Subcutaneous, near the injury |
| Chronic tendon or ligament issue | 250 to 500 mcg | once daily | Subcutaneous, near the injury or abdomen |
| Gut complaints | 250 to 500 mcg | once or twice daily | Oral capsule or subcutaneous |
| General recovery | 250 mcg | once daily | Subcutaneous, abdomen |
Food does not matter for injections. Oral doses for gut complaints are usually taken on an empty stomach so the peptide contacts the lining directly. Many people inject after training or in the evening, but there is no evidence that timing changes the result.
Commonly reported at 250 to 500 mcg once or twice daily. Some protocols go to 1 mg per day for acute injuries.
Dose calculator
U-100 insulin syringeUnits are a volume on the syringe, not an amount of peptide. Concentration changes every time you change the water volume. The standalone calculator explains the math.
| Vial | Suggested water | Concentration | Low dose draw |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 10 units |
| 10 mg | 2 mL | 5 mg/mL | 5 units |
How to reconstitute BPC-157
- 1
Wash your hands and wipe the work surface. Swab both vial stoppers with alcohol and let them dry.
- 2
Pick the water volume with the calculator above and write it on the vial. The concentration means nothing without it.
- 3
Draw the bacteriostatic water into a mixing syringe.
- 4
Insert at an angle and let the water run down the inside wall. Never squirt it straight onto the powder.
- 5
Swirl gently or leave it to dissolve. Do not shake.
- 6
Label with the date and water volume. Store in the fridge at 2 to 8 C and use within about 4 weeks.
- 7
Unmixed vials keep for months in the fridge and longer in the freezer, sealed and out of light.
- Full walkthrough with syringe reading and site rotation: reconstitution guide.
- ✓White, fluffy cake
Lyophilized powder should look like a small white puck or fluffy cake at the bottom of the vial. That is a proper freeze-dry.
- ✓Clear after mixing
Once dissolved the solution should be water-clear with nothing floating in it.
- !Slight clumping
Small clumps that dissolve with gentle swirling are fine. Shipping compacts powder.
- ✕Collapsed or melted
Powder stuck to the sides, glassy, or shrunken means it got hot in transit. Contact the vendor.
- ✕Cloudy or particles
Persistent cloudiness or visible particles after mixing means degraded or contaminated product. Do not use it.
- Days 1 to 7
Reduced pain and swelling at the injury is the most common early report; gut users often notice less discomfort in the first week.
- Week 2 to 4
Improved range of motion and load tolerance in tendon and muscle injuries; this matches the window where rodent tendon studies show measurable differences.
- Week 4 to 8
Chronic injuries continue to improve slowly or plateau; if nothing has changed by now, more of the same is unlikely to help.
Interactions and stacking
TB-500synergistic
The standard recovery pairing; TB-500 works systemically on cell migration while BPC-157 is dosed locally, and the two are thought to cover different steps of healing.
GHK-Cucompatible
Adds collagen remodeling for skin, scar and post-surgical healing; inject separately since copper can interact with other peptides in the same syringe.
KPVsynergistic
For gut protocols, KPV controls inflammation in the lining while BPC-157 promotes tissue repair.
Ipamorelincompatible
Growth hormone secretagogues are often added to recovery stacks; no known interaction, but the combination is untested.
NSAIDscompatible
Rodent studies show BPC-157 protects the stomach lining from NSAID damage, so there is no reason to avoid the combination, though it is not a substitute for limiting NSAID use.
Blood thinnerscaution
BPC-157 affects blood vessel growth and the nitric oxide system in animals; the effect on clotting in people taking anticoagulants is unknown.
Corticosteroid injectionscaution
Steroid injections can weaken tendon tissue, which works against what BPC-157 is being used for; talk to whoever gave the injection.
The classic recovery pairing. TB-500 works systemically on cell migration while BPC-157 is used locally, and the two are thought to cover different parts of the healing process.
GHK-Cu adds collagen remodeling and skin repair, so the pair is used for wound and post-surgical healing.
For gut-focused protocols, KPV adds direct anti-inflammatory action in the intestinal lining.
Safety
- ▲Injection site redness or mild irritation
- ▲Nausea, more often with oral capsules
- ▲Headache or brief dizziness after a dose
- ▲Transient fatigue or a warm flush shortly after injection
- ▲Rare reports of mood changes, possibly tied to its dopamine and serotonin effects in animals
- ▲Almost all evidence is from rats. Human dosing is extrapolated, not established.
- ▲Because it promotes new blood vessel growth, there is a theoretical concern about feeding existing tumors. No human data either way.
- ▲Prohibited in sport under WADA rules (S0, non-approved substances).
- ▲Reported side effects are mild: injection site irritation, nausea, occasional headache or dizziness.
- ▲Product quality varies a lot between vendors. Third party testing matters more than brand claims.
- ■A new lump, mass or unexplained growth appears anywhere, given the angiogenesis concern
- ■Pain or swelling at the injury gets worse rather than better after two weeks
- ■Signs of an allergic reaction such as hives, swelling or trouble breathing
- ■Persistent dizziness, palpitations or blood pressure changes
- ■You receive a cancer diagnosis or are starting cancer treatment
Community poll
Self-reported by visitors. Not clinical evidence.BPC-157: frequently asked
Does BPC-157 work orally?
It is stable in stomach acid and oral dosing worked in rodent gut studies, so oral use makes sense for stomach and intestinal complaints. For tendon or muscle injuries, most people inject it because the systemic absorption of oral peptide is uncertain. There is no human study comparing the two routes.
Do I need to inject it right at the injury?
Rodent studies show benefit with both local and systemic administration, so it is not strictly necessary. Many people still inject near the injury on the theory that local concentration helps. Never inject directly into a tendon or joint capsule unless you have clinical training.
Is BPC-157 legal?
It is not an approved drug anywhere. In the US it is sold as a research chemical, and in late 2023 the FDA placed it in the category of bulk substances that compounding pharmacies may not use. Possession for personal use is generally not a crime, but it cannot be legally sold for human consumption.
How fast does it work?
Anecdotally people report reduced pain within days and noticeable functional improvement over two to four weeks. Rodent tendon studies show measurable differences within a week. Chronic injuries tend to take longer than acute ones.
References
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review). Current Pharmaceutical Design, 2011
- Achilles tendon healing in rats with BPC 157, tendon-to-bone reattachment. Journal of Orthopaedic Research, 2003
- BPC 157 promotes tendon fibroblast outgrowth and migration via FAK-paxillin pathway. Journal of Applied Physiology, 2011
- Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (review). Current Neuropharmacology, 2016